ECTRUDYS Trademark

Trademark Overview


On Tuesday, May 6, 2025, a trademark application was filed for ECTRUDYS with the United States Patent and Trademark Office. The USPTO has given the ECTRUDYS trademark a serial number of 99172024. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, May 6, 2025. This trademark is owned by REGENXBIO Inc.. The ECTRUDYS trademark is filed in the Pharmaceutical Products category with the following description:

Biological preparations for medical use in the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Clinical medical reagents for use in gene therapy; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of genetic diseases and disorders, namely, Duchenne muscular dystrophy; Gene therapy preparation for medical use containing genetic materials for sustained protein expression...
ectrudys

General Information


Serial Number99172024
Word MarkECTRUDYS
Filing DateTuesday, May 6, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateTuesday, May 6, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesBiological preparations for medical use in the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Clinical medical reagents for use in gene therapy; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of genetic diseases and disorders, namely, Duchenne muscular dystrophy; Gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, microdystrophin expression

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 6, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameREGENXBIO Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Trademark Events


Event DateEvent Description
Tuesday, May 6, 2025NEW APPLICATION ENTERED
Tuesday, May 6, 2025APPLICATION FILING RECEIPT MAILED
Tuesday, May 6, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED